IN-VITRO ACTIVITIES OF BAY Y3118, CIPROFLOXACIN, OFLOXACIN, AND FLEROXACIN AGAINST GRAM-POSITIVE AND GRAM-NEGATIVE PATHOGENS FROM RESPIRATORY-TRACT AND SOFT-TISSUE INFECTIONS

BAY Y3118 was highly active against Moraxella catarrhalis, Haemophilus influenzae, Legionella pneumophila, Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus (except quinolone-resistant, methicillin-resistant S. aureus), Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus agalactiae, and Streptococcus pneumoniae (MIC for 90% of strains tested [MIC90], 0.063 mug/ml). For Enterococcus faecalis and Corynebacterium jeikeium, MIC90s were 4 and 2 mug/ml, respectively. BAY Y3118 was as active as ciprofloxacin against Pseudomonas aeruginosa (MIC90, 0.5 mug/ml) and had potent activity against Bacteroides fragilis (MIC90, 0.5 mug/ml).